[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 1988

Recommendations of the Immunization Practices Advisory Committee (ACIP) Update: Prevention of Haemophilus influenzae Type b Disease

Am J Dis Child. 1988;142(4):419-420. doi:10.1001/archpedi.1988.02150040069020

Jan 22, 1988 (Vol. 37, No. 2)—HAE-MOPHILUS b Conjugate Vaccine (Diphtheria Toxoid-Conjugate) has recently been licensed for use in children 18 months of age or older for the prevention of Haemophilus influenzae type b (Haemophilus b) disease. This vaccine consists of Haemophilus b capsular polysaccharide covalently linked to diphtheria toxoid (conjugate vaccine).

A previously developed vaccine consisting of the Haemophilus b capsular polysaccharide alone (polysaccharide vaccine) was shown to be effective in Finnish children over 24 months of age.1,2 A similar, but not identical, polysaccharide vaccine was licensed for use in the United States in April 1985 on the basis of data demonstrating biochemical characteristics and immunogenicity comparable to the vaccine used in the original Finnish trial.3 In that Finnish trial, polysaccharide vaccine was not effective in children less than 18 months of age. Because of the small sample size, efficacy could not be demonstrated in children 18 to 23